Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635 ...

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at aol.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

AbCellera announced positive Phase 2 clinical trial results for ABCL635, a non-hormonal antibody targeting NK3R to treat moderate-to-severe vasomotor symptoms in menopausal women, showing significant reduction in frequency and severity of hot flashes and improvements in sleep with favourable tolerability.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new opportunity to develop non-hormonal treatments for menopausal symptoms with a promising drug showing single-dose efficacy and tolerability. This opens a path to compete in women’s health with fewer safety concerns than hormone therapies.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialmenopausenon-hormonalvasomotor-symptomsbiotech